Unsatisfactory results of treating the malignant tumors of the brain induce the necessity of developing new technologies of treatment.

In A.L. Polenov's Research Institute of Neurosurgery since 2002, PDT technology has been developed in neuro-oncology with an assessment of its safety and effectiveness. PDT was performed in the treatment of 80 patients with malignant gliomas (grade III and IV) (2002–2019). Since 2023, the use of intraoperative PDT has been started in patients with secondary brain tumors (n=12) and in patients with recurrent anaplastic meningiomas (n=7),  the effectiveness of intraoperative PDT was investigated by studying morphological changes in the perifocal zone. The level of expression of the proapoptotic marker caspase-3 was assessed, and control MRI data were studied, (assessment of the perifocal zone in the mode Т2-WI, FLAIR, DWI), as well as assessment of the clinical and functional status of patients.

Due to its high selectivity of action, PDT is a promising technology compared to classical treatment methods used in neuro-oncology. The data obtained indicate a positive therapeutic effect of intraoperative PDT in the structure of complex treatment of patients with malignant tumors of the central nervous system.

In 2011, Kukanov K.K. graduated from the State Budgetary Educational Institution of Higher Professional Education “Vladivostok State Medical University” of the Ministry of Health and Social Development of Russia, majoring in “General Medicine” (diploma K No. 82976 dated June 28, 2011). In 2014, he was admitted to the Association of Neurosurgeons of St. Petersburg named after I. S. Babchina. In 2018, he earned the academic degree of Candidate of Medical Sciences (KNF diploma No. 043224) and was admitted to the Association of Neurosurgeons of Russia. In 2019, he became the Executive Secretary of the Russian Neurosurgical Journal prof. A. L. Polenova. Kukanov K.K. is the author of 72 published works, including co-authorship in monographs and national guidelines on neurosurgery. With an H-index (RSCI) of 6, he actively participates in international congresses and all-Russian conferences on neurosurgery, oncology, surgery, and neurology.